Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review

Vaccine

Volumn 31, Issue 37, 2013, Pages 3786-3804

  Fesenfeld, Michaela ^a   Hutubessy, Raymond ^a   Jit, Mark ^b,c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cervical screening; Cost effectiveness; Developing countries; Human papillomavirus; Vaccination

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; COCHRANE LIBRARY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA EXTRACTION; DECISION MAKING; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; ECONOMIC EVALUATION; EMBASE; EPIDEMIOLOGICAL DATA; FUNDING; HEALTH PROGRAM; HUMAN; LOWEST INCOME GROUP; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; UNCERTAINTY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS; WORLD HEALTH ORGANIZATION;

CERVICAL SCREENING; COST PER VACCINATED GIRL; COST-EFFECTIVENESS; CVG; DEVELOPING COUNTRIES; GDP; GROSS DOMESTIC PRODUCT; HPV; HUMAN PAPILLOMAVIRUS; ICER; INCREMENTAL COST-EFFECTIVENESS RATIO; LMIC; LOW OR MIDDLE INCOME COUNTRY; QALY; QUALITY ADJUSTED LIFE YEAR; VACCINATION; WHO; WORLD HEALTH ORGANIZATION;

COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; INCOME; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84881552751     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.060     Document Type: Review

References (60)

1. International Agency for Research on Cancer World Cancer Report 2008 2008, IARC Press, Lyon.
2. Bray F., Loos A.H., McCarron P., Weiderpass E., Arbyn M., Moller H., et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005, 14(March (3)):677-686.
3. Ferko N., Postma M., Gallivan S., Kruzikas D., Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine 2008, 26(September (Suppl. 5)):F3-F15.
4. Denny L., Quinn M., Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine 2006, 24(August (Suppl. 3)). S3-71-S3-77.
5. Gakidou E., Nordhagen S., Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 2008, 5(June (6)):e132.
6. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55(April (4)):244-265.
7. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(July (9686)):301-314.
8. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(May (19)):1915-1927.
9. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(May (19)):1928-1943.
10. Malagon T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(Oct (10)):781-789.
11. World Health Organization Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009, 84(April (15)):118-131.
12. Brisson M., Van d V., Boily M.C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12(5-6):343-351.
13. Kim J.J., Brisson M., Edmunds W.J., Goldie S.J. Modeling cervical cancer prevention in developed countries. Vaccine 2008, 26(August (Suppl. 10)):K76-K86.
14. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction - the first five years. Vaccine 2012, 30(November (Suppl. 5)):F139-F148.
15. Jit M., Demarteau N., Elbasha E., Ginsberg G., Kim J., Praditsitthikorn N., et al. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med 2011, 9:54.
16. Praditsitthikorn N., Teerawattananon Y., Tantivess S., Limwattananon S., Riewpaiboon A', Chichareon S., et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics 2011, 29(September (9)):781-806.
17. Termrungruanglert W., Havanond P., Khemapech N., Lertmaharit S., Pongpanich S., Khorprasert C., et al. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries. Value Health 2012, 15(January (1 Suppl.)):S29-S34.
18. Sharma M., Ortendahl J., van der H.E., Sy S., Kim J.J. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG 2012, 119(January (2)):166-176.
19. The World Bank. Country and lending groups, [accessed 15.01.13]. http://data.worldbank.org/about/country-classifications/country-and-lending-groups.
20. The World Bank. GDP per capita (current US$), [accessed 15.01.13]. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
21. United Nations Statistics Division. Millenium Development Goals Indicators. The official United Nations site for the MDG Indicators. Series name: Purchasing power parities (PPP) conversion factor, local currency unit to international dollar, [accessed 15.01.13]. http://unstats.un.org/unsd/mdg/SeriesDetail.aspx%3Fsrid=699.
22. United States Department of Labor. Bureau of Labor Statistics. Consumer price index, [accessed 15.01.13]. http://www.bls.gov/cpi/.
23. US Bureau of Labor. Inflation calculator.
24. Board of Governors of the Federal Reserve System. Foreign exchange rates - H.10, [accessed 15.01.13]. http://www.federalreserve.gov/releases/h10/hist/default.htm.
25. Goldie S.J., O'Shea M., Campos N.G., Diaz M., Sweet S., Kim S.Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26(July (32)):4080-4093.
26. Ginsberg G.M., Edejer T.T., Lauer J.A., Sepulveda C. Screening, prevention and treatment of cervical cancer - a global and regional generalized cost-effectiveness analysis. Vaccine 2009, 27(October (43)):6060-6079.
27. Jit M., Levin C., Brison M., Levin A., Resch S., Berkhof J., et al. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. BMC Med 2013, 11(January (1)):23.
28. Kim J.J., Kobus K.E., Diaz M., O'Shea M., Van Minh H., Goldie S.J. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 2008, 26(July (32)):4015-4024.
29. Diaz M., Kim J.J., Albero G., de Sanjose S., Clifford G., Bosch F.X., et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008, 99(July (2)):230-238.
30. Sinanovic E., Moodley J., Barone M.A., Mall S., Cleary S., Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine 2009, 27(October (44)):6196-6202.
31. Kim J.J., Andres-Beck B., Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007, 97(November (9)):1322-1328.
32. Insinga R.P., Dasbach E.J., Elbasha E.H., Puig A., Reynales-Shigematsu L.M. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007, 26(December (1)):128-139.
33. Tan-Torres Edejer T., Baltussen R., Adam T., et al. Making choices in health: WHO guide to cost-effectiveness analysis 2003, World Health Organisation, Geneva.
34. Shillcutt S.D., Walker D.G., Goodman C.A., Mills A.J. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009, 27(11):903-917.
35. Demarteau N., Breuer T., Standaert B. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics 2012, 30(April (4)):337-353.
36. Kim S.Y., Sweet S., Chang J., Goldie S.J. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. BMC Infect Dis 2011, 11:174.
37. Myers E.R., McCrory D.C., Nanda K., Bastian L., Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000, 151(June (12)):1158-1171.
38. Goldie S.J., Grima D., Kohli M., Wright T.C., Weinstein M., Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003, 106(October (6)):896-904.
39. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'shea M.K., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007, 25(August (33)):6257-6270.
40. Colantonio L., Gomez J.A., Demarteau N., Standaert B., Pichon-Riviere A., Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009, 27(September (40)):5519-5529.
41. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13(January (1)):28-41.
42. Reynales-Shigematsu L.M., Rodrigues E.R., Lazcano-Ponce E. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 2009, 40(August (6)):503-513.
43. Noninfluenza vaccination coverage among adults - United States, 2011. MMWR Morb Mortal Wkly Rep 2013, 62(February):66-72.
44. Dorleans F., Giambi C., Dematte L., Cotter S., Stefanoff P., Mereckiene J., et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010, 15(47).
45. Quentin W., Terris-Prestholt F., Changalucha J., Soteli S., Edmunds W.J., Hutubessy R., et al. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC Med 2012, 10:137.
46. Gutierrez-Aguado A. [Cost-utility of the vaccine against the human papiloma virus in Peruvian women]. Rev Peru Med Exp Salud Publica 2011, 28(July (3)):416-425.
47. Canfell K., Shi J.F., Lew J.B., Walker R., Zhao F.H., Simonella L., et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 2011, 29(March (13)):2487-2494.
48. Ezat S.W., Aljunid S. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev 2010, 11(4):943-951.
49. Ezat W.P., Aljunid S. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev 2010, 11(1):79-90.
50. Hutubessy R., Levin A., Wang S., Morgan W., Ally M., John T., et al. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. BMC Med 2012, 10:136.
51. Walker D.G., Hutubessy R., Beutels P. WHO guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010, 28(March (11)):2356-2359.
52. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal, June 2008.
53. Vanagas G., Padaiga Z., Kurtinaitis J., Logminiene Z. Cost-effectiveness of 12- and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania. Scand J Public Health 2010, 38(August (6)):639-647.
54. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359(August (8)):821-832.
55. Dasbach E.J., Elbasha E.H., Insinga R.P. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006, 28:88-100.
56. GAVI Alliance. GAVI funds vaccines to protect girls against cervical cancer, [accessed 1.02.13]. http://www.gavialliance.org/library/news/press-releases/2013/gavi-funds-vaccines-to-protect-girls-against-cervical-cancer/.
57. Goldie S.J., Diaz M., Kim S.Y., Levin C.E., Van Minh H., Kim J.J. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008, 26(August (Suppl. 12)):M17-M29.
58. Moon S., Jambert E., Childs M., Schoen-Angerer T. A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health 2011, 7(1):39.
59. Gutierrez-Delgado C., Baez-Mendoza C., Gonzalez-Pier E., de la Rosa A.P., Witlen R. [Generalized cost-effectiveness of preventive interventions against cervical cancer in Mexican women: results of a Markov model from the public sector perspective]. Salud Publica Mex 2008, 50(March (2)):107-118.
60. Craig B.M., Brisson M., Chesson H., Giuliano A.R., Jit M. Proceedings of the modeling evidence in HPV pre-conference workshop in Malmo, Sweden, May 9-10, 2009. Clin Ther 2010, 32(August (8)):1546-1564.